Drug
S247240 Low Dose
S247240 Low Dose: highest development phase Phase 2, developed by Institut de Recherches Internationales Servier (I.R.I.S.). 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Institut de Recherches Internationales Servier (I.R.I.S.)
Trials
| Drug | Phase | Indication |
|---|---|---|
| S247240 Low dose NCT07930520 | Phase 2 | Fragile X Syndrome (FXS) |
Latest
No recent events.
Follow S247240 Low Dose on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.